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Case 
report
Abstract
We report a case of a false-positive finding in FDG PET/CT fol-
lowing radiotracer extravasation. A 15-year-old male patient was 
referred for therapeutic evaluation status post-chemotherapy for 
a lymphoblastic lymphoma. FDG PET/CT showed discordant 
findings with a marked decrease in a liver/hepatic hilum uptake, 
disappearance of a subcutaneous left supraclavicular uptake, and 
appearance of intense right axillary nodal uptake. Extravasation in 
the right superior limb was noted. Comparison with the previous 
scan showed that the axillary nodes were present, measured less 
than 1 cm in their short axis, had not increased in size, and had 
a fatty hilum. We concluded that FDG uptake was caused by a 
migration in lymphatic vessels.
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Introduction
FDG PET/CT is increasingly being used and investigated 
for therapy response in a wide variety of cancers, e.g. lung 
cancer [1], rectal cancer [2], oesophageal cancer [3], and 
lymphoma [4] and in a larger number of indications: neoadju-
vant chemotherapy in breast cancer [5],  radiochemotherapy 
in rectal cancer [6], and early response to chemotherapy in 
lymphoma [7]. Hodgkin’s disease and non-Hodgkin lymphoma 
are two malignancies where FDG PET has become central for 
appropriate patient management. The accuracy of therapy 
response assessment is therefore paramount and nuclear 
medicine physicians must be aware of all pitfalls and causes of 
false-positive and false-negative findings with FDG PET/CT. We 
describe a false-positive finding in a young male patient follow-
ing radiotracer extravasation.
Case report
A 15-year-old male patient was referred to our institute for thera-
peutic evaluation status post-chemotherapy for a lymphoblastic 
lymphoma. FDG PET/CT was compared to the pretherapeutic 
scan. Discordant findings were noted: there was a marked de-
crease in a previous liver/hepatic hilum uptake, disappearance 
of a subcutaneous left supraclavicular uptake, and appearance 
of intense right axillary nodal uptake (Figure 1). There was a large 
area of radiotracer uptake within subcutaneous tissue of the 
right superior limb, consistent with extravasation (Figure 2). 
The axillary nodes were present on the previous scan, were not 
hypermetabolic, measured less than 1 cm in their short axis, 
had not increased in size, and had a fatty hilum (Figure 3) . The 
discordant findings led us to hypothesize that the right axillary 
lymph node uptake was due to radiotracer extravasation to the 
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subcutaneous tissue and radiotracer incorporation within lymphatic 
vessels and lymph nodes. We concluded that the axillary lymph 
node uptake was a false-positive and that the patient was in partial 
metabolic response. 
Discussion
Therapy response assessment is a critical step in patient 
management and has become an increasingly important 
part of our daily clinical workload at PET/CT centres. Discor-
dant findings are some of the most difficult situations to be 
confronted with. A deep understanding of pathologies and of 
therapeutics alongside extensive technical skills has become 
indispensable for nuclear medicine physicians, and will help 
when reporting on complex scans. The case report we describe 
here is an example of a complex scan where discordant find-
ings are to be interpreted in the context of an overall decrease 
or disappearance of previous FDG uptake sites and where the 
appearance of an FDG avid lymph node is situated next to 
an area of radiotracer extravasation. FDG accumulation within 
the axilla following subcutaneous radiotracer infiltration has been 
described before with FDG [8] and with bone tracer MDP [9]. 
We feel that it is important for nuclear medicine physicians to be 
aware of this cause of false-positive findings, especially in a time 
where patient management in oncology depends increasingly on 
FDG PET/CT results.
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Figure 1. Intense FDG uptake within a right axillary lymph node. The 
lymph node has a fatty hilum and measures less than 1 cm in its 
short axis. MIP images show radiotracer extravasation within the right 
superior limb and intense FDG uptake within the right axillary fossa. 
Top left: axial CT section; top right: coronal PET section; bottom left: 
axial PET section; bottom right: MIP.
Figure 2. Intense FDG accumulation within subcutaneous tissue of 
the right superior limb caused by radiotracer extravasation. Top left: 
axial CT section; bottom left: axial PET section; top right: coronal CT 
section; bottom right: coronal PET section.
Figure 3. Comparison with the previous FDG PET/CT of two months 
earlier. Appearance of intense FDG uptake within right axillary lymph 
nodes. Comparison on the CT does not show an increase in size, nodes 
present with a fatty hilum and are subcentimetric in their short axis. 
A. Axial interim CT; B. Axial interim PET; C. Axial pre-therapeutic CT; 
D. Axial pre-therapeutic PET.
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